ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Impact of the Indonesian National Health Insurance Implementation on Prostate Cancer Detection, Staging, and Treatment in West Java Province, Indonesia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the impact of National Health Insurance/ Jaminan Kesehatan Nasional (JKN) implementation on prostate cancer detection, staging, and treatment in West Java Province, Indonesia, with a focus on changes in prostate-specific antigen (PSA) testing accessibility.
methodsThis cross-sectional study retrospectively analyzed medical records from Hasan Sadikin Hospital, a tertiary referral center, to compare prostate cancer cases between 2009-2013 (pre-JKN) and 2015-2019 (post-JKN). Data included age at diagnosis, PSA levels, Gleason grade, T and M stages, and treatment modalities. Additionally, a survey of urologists in West Java was conducted to assess PSA testing practices and JKN coverage. Statistical analyses were performed using Chi-square and Mann-Whitney U-tests.
resultsFollowing JKN implementation, a significant increase in median PSA levels (from 29.275 ng/ml to 85.845 ng/ml, p=0.002) was observed. This was accompanied by a shift towards higher Gleason grade groups (p<0.001), more advanced T stages (p<0.001), and advanced M stages (p=0.003). The survey revealed limited PSA testing coverage under JKN, with only 18.75% of urologists reporting availability at their hospitals.
conclusionLimited PSA testing following JKN implementation resulted in an increase in median PSA levels and a shift toward more advanced disease, suggesting an inability to detect prostate cancer at an early stage. These findings underscore the urgent need for targeted policy adjustments to enhance early detection, particularly in primary care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.